Compile Data Set for Download or QSAR
Report error Found 24 Enz. Inhib. hit(s) with all data for entry = 8520
Target5-hydroxytryptamine receptor 2B(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataEC50: >1.00E+4nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetGamma-aminobutyric acid receptor subunit alpha-1(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataIC50: 1.00E+5nMAssay Description:Activity of compounds on native GABAA receptors is evaluated by monitoring calcium fluxes using a 96 well format FLIPR system (Fluorometric Imaging P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  3.37nM ΔG°:  -48.4kJ/molepH: 7.6 T: 2°CAssay Description:[3H]-Ketanserin binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  7.01nM ΔG°:  -46.5kJ/molepH: 7.6 T: 2°CAssay Description:[3H]-Ketanserin binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetHistamine H1 receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  20.6nM ΔG°:  -43.9kJ/molepH: 7.6 T: 2°CAssay Description:[3H]-Pyrilamine binding experiments are carried out in SPA (scintillation proximity assay) 96-well format. Membranes used in this assay are prepared ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetHistamine H1 receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  58.8nM ΔG°:  -41.3kJ/molepH: 7.6 T: 2°CAssay Description:[3H]-Pyrilamine binding experiments are carried out in SPA (scintillation proximity assay) 96-well format. Membranes used in this assay are prepared ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2B(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  121nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  137nM ΔG°:  -39.2kJ/moleT: 2°CAssay Description:[125I]-(±)DOI binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  328nM ΔG°:  -37.0kJ/moleT: 2°CAssay Description:[125I]-(±)DOI binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  592nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 7(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >2.06E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi:  2.78E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1D(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >3.98E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetAlpha-2C adrenergic receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >4.23E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >4.57E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetD(3) dopamine receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >5.51E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1B(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >5.58E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetD(3) dopamine receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >5.68E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetAlpha-2B adrenergic receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >5.76E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 6(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >5.83E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 5A(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >8.81E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetAlpha-2A adrenergic receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >8.99E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetAlpha-1A adrenergic receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >1.02E+4nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetAlpha-1B adrenergic receptor(Human)
Eli Lilly

US Patent
LigandPNGBDBM255474(US9481688, 1 | US9481688, 3)
Affinity DataKi: >1.47E+4nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent